21 papers in the library · 14 citations · publishing 2025-2026
ACS Medicinal Chemistry Letters August 13, 2026 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel tetrahydropyridinyl-6,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters July 3, 2026 Ram W. Sabnis, Anika R. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel 6,5-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse, and headaches, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 3, 2026 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel 5,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters May 7, 2026 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel tricyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel indoline derivatives serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters October 22, 2025 Ram W. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel psilocin derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters August 25, 2025 Ram W. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters August 14, 2025 Ram W. Sabnis
Provided herein are novel nonhallucinogenic compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental health disorders, namely depression, anxiety, stress disorders and eating disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 29, 2025 Ram W. Sabnis
Provided herein are novel tricyclic psychedelic psychoplastogens as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating neurological diseases, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 19, 2025 Ram W. Sabnis
Provided herein are novel phenoxy and benzyloxy substituted psychedelic psychoplastogens as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating neurological diseases, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 16, 2025 Ram W. Sabnis
Provided herein are novel N-substituted indole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 12, 2025 Ram W. Sabnis 4 citations
Provided herein are novel indole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 11, 2025 Ram W. Sabnis
Provided herein are novel benzofuran and benzothiophene psychedelic psychoplastogens as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating neurological diseases, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters June 10, 2025 Ram W. Sabnis
Provided herein are novel indazole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters March 13, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A receptor modulators, pharmaceutical compositions, use of such compounds in treating psychiatric and neurological disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters February 11, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental illness or CNS disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
Provided herein are novel indoline derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 23, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel pyrrolopyridine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental illnesses, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 9, 2025 Ram W. Sabnis 7 citations
Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 4, 2025 Ram W. Sabnis
Provided herein are novel 3-cycloaminoindole compounds as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.